Alopexx (ALPX) sets $10-$12 IPO range after dozens of amendments

Alopexx, Inc. (ALPX), an anti-infective drug developer, has set an IPO price range of $10-$12 per share, with 3 million shares offered. ThinkEquity is leading the underwriting. The small float may lead to significant price volatility post-listing on NYSE American. The final price is pending.

Original reporting
Published Nov 6, 2026, 9:44 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 6, 2026, 11:33 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Alopexx (ALPX) sets $10-$12 IPO range after dozens of amendments — source image
Decision brief

The 30-second read

$ALPXNeutralMed
01

Why it matters

The disclosed price range and share count set expectations for the debut, but the final price will determine the actual market reaction.

02

Market read

Primary disclosure of IPO terms for a micro‑cap biotech; relevance mainly to IPO‑focused traders.

03

What to watch

Potential demand from institutional investors and the reputation of ThinkEquity as bookrunner could stabilize the debut.

Relevance 5/10Novelty 6/10Timing: pre‑market today

Background

Alopexx is an anti‑infective drug developer that has filed multiple SEC amendments before finalizing its IPO terms.

Company-level read

Ticker impact

$ALPXNeutralMedium confidence
Context

The company announced its IPO price range of $10‑$12 per share for 3 million shares, the first public disclosure of the offering terms.

Expected impact

likely pressure both up and down as the market prices the thin float debut

Evidence & confidence

IPO pricing range is set but final price unknown; thin supply typically amplifies price swings in initial trading.

Market effects

Adds another micro‑cap biotech offering to the biotech IPO pipeline, modest impact on sector supply.

US market sees a new listing on NYSE American; limited broader regional effect.

Low global relevance beyond niche biotech investors.

Counterpoint

Investors may avoid the IPO due to uncertainty over final pricing and potential volatility.

Key entities

  • Alopexx, Inc.

    Anti‑infective drug developer filing for IPO.

  • ThinkEquity

    Bookrunner for the IPO.

Related articles

$ANTHighAI 9/10

Anthropic IPO Priced at $83: The $1.5 Trillion Math

Anthropic's IPO priced at $83 per share, raising $81.3B, the largest IPO on record. The company increased the deal size to 980M shares, with trading set to begin on Nasdaq under ticker ANT. The valuation reached ~$1.1T post-IPO, with a fully diluted valuation of ~$1.5T. Anthropic's revenue run rate was $81B as of October 31, 2026.

$ANTMed

Anthropic CFO calls IPO ‘one stop on the train’: Bloomberg

Anthropic's CFO Krishna Rao stated the company's IPO, which raised $93.5 billion, aims to improve capital access and democratize ownership. Rao emphasized long-term growth and conservative financial management, highlighting the company's rapid revenue growth to $81 billion run rate. Anthropic, known for AI platform Claude, has 11,900 enterprise customers, prioritizing safety and capability.

$ANTMedAI 8/10

Anthropic Prices Record IPO in a Market – and World – on Edge

Anthropic completed the largest IPO in history, pricing at $83 per share and raising $81.3 billion. Shares began trading at $111.50, up 34%, but fell to $94.67 by afternoon. The company, known for its Claude chatbot, is valued at roughly $1.5 trillion. The IPO occurred amidst broader market sell-offs and concerns about AI risks and economic uncertainty.